OTLK
Outlook Therapeutics Inc.
$0.44
+$0.00(+0.07%)
30
Overall
40
Value
16
Tech
34
Quality
Market Cap
$36.55M
Volume
807.68K
52W Range
$0.42 - $3.39
Target Price
$6.10
Order:
Income Statement
| Metric | Trend | Chart | 2016 Sep | 2017 Sep | 2018 Sep | 2019 Sep | 2020 Sep | 2021 Sep | 2022 Sep | 2023 Sep | 2024 Sep | 2025 Sep |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | $3.0M | $3.8M | $3.1M | $8.1M | -- | -- | -- | -- | -- | $1.4M | ||
| Total Revenue | $3.0M | $3.8M | $3.1M | $8.1M | -- | -- | -- | -- | -- | $1.4M | ||
| COST OF GOODS SOLD | ||||||||||||
| Cost of Revenue | -- | -- | -- | -- | -- | -- | -- | -- | -- | $1.4M | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | $3.0M | $3.8M | $3.1M | $8.1M | -- | -- | -- | -- | -- | $57.2K | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $-54.3M | $-39.7M | $-32.7M | $-44.4M | $36.8M | $51.7M | $63.1M | $53.1M | $71.7M | $67.1M | ||
| Research & Development | $32.8M | $23.8M | $20.4M | $24.4M | $26.3M | $39.0M | $42.3M | $26.5M | $41.8M | $27.2M | ||
| Research Expense | $32.8M | $23.8M | $20.4M | $23.8M | $26.3M | $39.0M | $42.3M | $26.5M | $41.8M | $27.2M | ||
| Selling, General & Administrative | $21.6M | $15.9M | $14.2M | $9.4M | $10.0M | $12.8M | $20.7M | $26.7M | $29.9M | $39.9M | ||
| General & Administrative Expenses | $21.6M | $15.9M | $14.2M | $9.4M | $10.0M | $12.8M | $20.7M | $26.7M | $29.9M | $39.9M | ||
| Salaries & Wages | $-98.2K | -- | -- | $-1.3M | -- | -- | -- | $5.5M | -- | -- | ||
| Depreciation & Amortization | $-2.4M | $-2.7M | $-3.1M | $-3.4M | $219.4K | $163.6K | $163.6K | -- | -- | -- | ||
| Depreciation & Amortization | $-2.4M | $-2.7M | $-3.1M | $-3.4M | $219.4K | $163.6K | $163.6K | -- | -- | -- | ||
| Amortization | -- | -- | -- | -- | $183.0K | -- | -- | -- | -- | -- | ||
| Other Operating Expenses | $-100.0K | $-497.5K | -- | -- | $1.3M | $112.0K | $48.0K | $46.3K | -- | -- | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $-51.3M | $-35.9M | $-31.5M | $-25.7M | $-36.8M | $-51.7M | $-63.1M | $-53.1M | $-71.7M | $-67.1M | ||
| EBITDA | $-49.0M | $-30.0M | $-26.8M | $-33.9M | $-36.2M | $-52.0M | $-64.4M | $-58.9M | $-72.1M | $-63.6M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | $1.9M | $5.6M | $3.9M | $3.5M | $1.8M | $936.1K | $1.5M | $1.4K | $3.2M | $283.1K | ||
| Intinc | -- | -- | -- | -- | -- | -- | -- | $971.5K | $906.1K | $89.7K | ||
| Net Non-Operating Interest Income/Expense | $-1.9M | $-5.6M | $-3.9M | $-3.5M | $-1.8M | $-936.1K | $-1.5M | $971.5K | $-2.3M | $-193.4K | ||
| Gain on Sale of Securities | -- | -- | $-4.2M | -- | -- | -- | -- | -- | -- | -- | ||
| Other Income/Expense | -- | $-3.2M | $204.6K | $-1.8M | $1.9M | $498.5K | $-1.5M | $537.7K | $-38.5M | $-42.9M | ||
| Other Special Charges | -- | $3.2M | $-204.6K | $1.8M | $-1.7M | $-452.1K | $-559.6K | $-526.7K | $38.6M | $43.0M | ||
| SPECIAL ITEMS | ||||||||||||
| Restructring And Mn A Income | -- | -- | -- | -- | $-900.0K | -- | -- | -- | -- | -- | ||
| Special Income Charges | -- | -- | $-1.9M | $-11.3M | $-527.6K | -- | -- | -- | -- | -- | ||
| Impairment of Capital Assets | -- | -- | -- | $11.3M | $527.6K | -- | -- | -- | -- | -- | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $-51.3M | $-32.7M | $-29.8M | $-37.3M | $-36.8M | $-52.2M | $-64.6M | $-59.0M | $-72.2M | $-63.7M | ||
| Pre-Tax Income | $-53.2M | $-38.3M | $-33.7M | $-37.9M | $-38.5M | $-53.2M | $-66.0M | $-59.0M | $-75.4M | $-64.0M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | $103.0K | $501.5K | $-3.6M | $-3.4M | $-3.3M | $2.0K | $2.8K | $2.8K | $2.8K | $-1.6M | ||
| NET INCOME | ||||||||||||
| Net Income | $-53.3M | $-38.8M | $-32.0M | $-35.1M | $-35.2M | $-53.2M | $-66.1M | $-59.0M | $-75.4M | $-62.4M | ||
| Net Income (Continuing Operations) | $-53.3M | $-38.8M | $-32.0M | $-35.1M | $-35.2M | $-53.2M | $-66.1M | $-59.0M | $-75.4M | $-62.4M | ||
| Net Income (Discontinued Operations) | $-53.3M | $-38.8M | $-32.0M | $-35.1M | $-35.2M | $-53.2M | $-66.1M | $-59.0M | $-75.4M | $-62.4M | ||
| Net Income (Common Stockholders) | $-63.1M | $-40.0M | $-48.0M | $-36.0M | $-48.9M | $-53.2M | $-66.1M | $-59.0M | $-75.4M | $-62.4M | ||
| Normalized Income | -- | -- | -- | -- | -- | $-42.0M | -- | -- | -- | $-65.5M | ||
| TOTALS | ||||||||||||
| Total Expenses | $-54.3M | $-39.7M | $-32.7M | $-44.4M | $36.8M | $51.7M | $63.1M | $53.1M | $71.7M | $68.5M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $107.6K | $3.0M | $4.9M | $18.2M | $72.6M | $152.7M | $10.6M | $12.5M | $18.5M | $34.8M | ||
| Average Shares Outstanding (Diluted) | $90.8K | $3.0M | $4.9M | $17.8M | $72.6M | $152.7M | $10.6M | $12.5M | $18.5M | $34.8M | ||
| Shares Outstanding | $147.4K | $3.2M | $10.6M | $30.1M | $6.4M | $224.3M | $64.1M | $13.0M | $24.9M | $64.1M | ||
| Basic EPS | -- | $-13.36 | $-9.76 | -- | $-0.67 | $-0.35 | $-6.2 | $-4.8 | $-4.06 | $-1.79 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | -- | $-0.67 | $-0.35 | $-6.2 | $-4.8 | $-4.06 | $-1.79 | ||
| Diluted EPS | $-587.2 | $-14.4 | $-9.76 | $-1.98 | $-0.67 | $-0.35 | $-6.2 | $-4.8 | $-4.06 | $-1.79 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | -- | -- | $-0.35 | $-6.2 | $-4.8 | $-4.06 | $-1.79 | ||
| OTHER METRICS | ||||||||||||
| Accretion On Preferred Stock | $2.5M | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Accrued Preferred Stock Dividends | $7.4M | $1.2M | $16.0M | $890.9K | $13.5M | -- | -- | -- | -- | -- | ||
| Development Expense | -- | -- | -- | $625.0K | -- | -- | -- | -- | -- | -- | ||
| Earnings from equity interest | -- | -- | -- | -- | -- | $-46.3K | $-48.7K | $-11.0K | $-100.7K | $-141.0K | ||
| Earnings From Equity Interest Net Of Tax | -- | -- | -- | -- | -- | $-46.3K | $-48.7K | $-11.0K | $-100.7K | $-141.0K | ||
| Gain On Sale Of P P E | -- | -- | -- | -- | $-680.0K | $552.3K | -- | -- | -- | -- | ||
| Interest Expense Operating | -- | -- | -- | $-2.8M | $-914.0K | -- | -- | -- | -- | -- | ||
| Minority Interests | $654.4K | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Other Gand A | $21.6M | $15.9M | $14.2M | $9.4M | $10.0M | $12.8M | $20.7M | $26.7M | $29.9M | $39.9M | ||
| Other Impairment Of Capital Assets | -- | -- | -- | -- | $166.1K | -- | -- | -- | -- | -- | ||
| Otherunder Preferred Stock Dividend | $9.8M | $1.2M | $16.0M | $890.9K | $13.5M | -- | -- | -- | -- | -- | ||
| Preferred Stock Dividends | $9.8M | $1.2M | $16.0M | $890.9K | $13.5M | -- | -- | -- | -- | -- | ||
| Rent And Landing Fees | $21.6M | $15.9M | $14.2M | $9.4M | -- | -- | -- | -- | -- | -- | ||
| Othspecchg | -- | -- | $1.9M | -- | -- | -- | -- | -- | -- | -- | ||
| Restruct | -- | -- | -- | -- | $-900.0K | -- | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | OTLK | $0.44 | +0.1% | 807.68K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Outlook Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW